De-immunized and Functional Therapeutic (DeFT) versions of a long lasting recombinant alpha interferon for antiviral therapy | ||
| dc.conicet.organizacion | Consejo Nacional de Investigaciones Científicas y Técnicas | |
| dc.conicet.organizacion | Universidad Nacional del Litoral | |
| dc.conicet.organizacion | Consejo Nacional de Investigaciones Científicas y Técnicas | |
| dc.conicet.organizacion | Universidad Nacional del Litoral | |
| dc.conicet.organizacion | Consejo Nacional de Investigaciones Científicas y Técnicas | |
| dc.conicet.organizacion | Universidad Nacional del Litoral | |
| dc.conicet.organizacion | EpiVax Incorporated | |
| dc.conicet.organizacion | EpiVax Incorporated | |
| dc.conicet.organizacion | EpiVax Incorporated | |
| dc.conicet.organizacion | University of Rhode Island | |
| dc.contributor.author | Mufarrege, Eduardo Federico | |
| dc.contributor.author | Giorgetti, Sofia Inés | |
| dc.contributor.author | Etcheverrigaray, Marina | |
| dc.contributor.author | Terry, Frances | |
| dc.contributor.author | Martin, William | |
| dc.contributor.author | De Groot, Anne S. | |
| dc.date.issued | 2017-01 | |
| dc.description.abstract | Interferon α (IFN-α) exerts potent antiviral, immunomodulatory, and antiproliferative activity and have proven clinical utility in chronic hepatitis B and C virus infections. However, repeated IFN-α administration induces neutralizing antibodies (NAb) against the therapeutic in a significant number of patients. Associations between IFN-α immunogenicity and loss of efficacy have been described. So as to improve the in vivo biological efficacy of IFN-α, a long lasting hyperglycosylated protein (4N-IFN) derived from IFN-α2b wild type (WT-IFN) was developed. However, in silico analysis performed using established in silico methods revealed that 4N-IFN had more T cell epitopes than WT-IFN. In order to develop a safer and more efficient IFN therapy, we applied the DeFT (De-immunization of Functional Therapeutics) approach to producing functional, de-immunized versions of 4N-IFN. Using the OptiMatrix in silico tool in ISPRI, the 4N-IFN sequence was modified to reduce HLA binding potential of specific T cell epitopes. Following verification of predictions by HLA binding assays, eight modifications were selected and integrated in three variants: 4N-IFN(VAR1), (VAR2) and (VAR3). Two of the three variants (VAR1 and VAR3) retained anti-viral function and demonstrated reduced T-cell immunogenicity in terms of T-cell proliferation and Th1 and Th2 cytokine levels, when compared to controls (commercial NG-IFN (non-glycosylated), PEG-IFN, WT-IFN and 4N-IFN). It was previously demonstrated that N-glycosylation improved IFN-α pharmacokinetic properties. Here, we further reduce immunogenicity as measured in vitro using T cell assays and cytokine profiling by modifying the T cell epitope content of a protein (de-immunizing). Taking into consideration the present results and previously reported immunogenicity data for commercial IFN-α2b variants, 4N-IFN(VAR1) and 4N-IFN-4N(VAR3) appear to be promising candidates for improved IFN-α therapy of HCV and HBV. | es |
| dc.description.fil | Fil: Mufarrege, Eduardo Federico. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional del Litoral; Argentina | |
| dc.description.fil | Fil: Giorgetti, Sofia Inés. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional del Litoral; Argentina | |
| dc.description.fil | Fil: Etcheverrigaray, Marina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional del Litoral; Argentina | |
| dc.description.fil | Fil: Terry, Frances. EpiVax Incorporated; Estados Unidos | |
| dc.description.fil | Fil: Martin, William. EpiVax Incorporated; Estados Unidos | |
| dc.description.fil | Fil: De Groot, Anne S.. EpiVax Incorporated; Estados Unidos. University of Rhode Island; Estados Unidos | |
| dc.format | application/pdf | es |
| dc.identifier.citation | Mufarrege, Eduardo Federico; Giorgetti, Sofia Inés; Etcheverrigaray, Marina; Terry, Frances; Martin, William; et al.; De-immunized and Functional Therapeutic (DeFT) versions of a long lasting recombinant alpha interferon for antiviral therapy; Academic Press Inc Elsevier Science; Clinical Immunology; 176; 1-2017; 31-41 | es |
| dc.identifier.institucional | CONICET | |
| dc.identifier.issn | 1521-6616 | es |
| dc.identifier.repo | CONICET Digital | |
| dc.identifier.uri | http://hdl.handle.net/11336/115726 | |
| dc.journal.ciudad | Amsterdam | es |
| dc.journal.pagination | 31-41 | es |
| dc.journal.pais | Países Bajos | es |
| dc.journal.title | Clinical Immunology | es |
| dc.journal.volume | 176 | es |
| dc.language.iso | eng | es |
| dc.publisher | Academic Press Inc Elsevier Science | es |
| dc.relation.alternativeid | info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1016/j.clim.2017.01.003 | |
| dc.rights | info:eu-repo/semantics/openAccess | * |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ | * |
| dc.subject | DE-IMMUNIZATION | es |
| dc.subject | HEPATITIS THERAPY | es |
| dc.subject | IFN ALPHA | es |
| dc.subject | IFN-Α | es |
| dc.subject | IMMUNOGENICITY | es |
| dc.subject | IN SILICO PREDICTION | es |
| dc.subject | T CELL EPITOPE | es |
| dc.subject | T-CELL PROLIFERATION ASSAY | es |
| dc.subject.classification | Biotecnología relacionada con la Salud | es |
| dc.subject.classification | Biotecnología de la Salud | es |
| dc.subject.classification | CIENCIAS MÉDICAS Y DE LA SALUD | es |
| dc.title | De-immunized and Functional Therapeutic (DeFT) versions of a long lasting recombinant alpha interferon for antiviral therapy | es |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:ar-repo/semantics/artículo | |
| dc.type | info:eu-repo/semantics/publishedVersion | |
Archivos
Bloque original
Cargando...
- Nombre:
- CONICET_Digital_Nro.47896be4-7970-4b3a-baa6-274ec59df36f_D.pdf
- Tamaño:
- 3.71 MB
- Formato:
- Adobe Portable Document Format